Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.320
0.00 (0.00%)
At close: Dec 20, 2024, 4:00 PM
1.330
+0.010 (0.76%)
After-hours: Dec 20, 2024, 6:53 PM EST
Repare Therapeutics Employees
Repare Therapeutics had 179 employees as of December 31, 2023. The number of employees decreased by 1 or -0.56% compared to the previous year.
Employees
179
Change (1Y)
-1
Growth (1Y)
-0.56%
Revenue / Employee
$371,642
Profits / Employee
-$469,542
Market Cap
56.11M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 179 | -1 | -0.56% |
Dec 31, 2022 | 180 | 28 | 18.42% |
Dec 31, 2021 | 152 | 50 | 49.02% |
Dec 31, 2020 | 102 | 38 | 59.38% |
Dec 31, 2019 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
VolitionRx | 110 |
Aadi Bioscience | 89 |
Connect Biopharma Holdings | 81 |
Boundless Bio | 72 |
Immuneering | 68 |
Kronos Bio | 63 |
Spero Therapeutics | 46 |
RPTX News
- 8 days ago - Why Is Repare Therapeutics Stock Trading Lower On Friday? - Benzinga
- 9 days ago - Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
- 11 days ago - Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - Business Wire
- 5 weeks ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 6 weeks ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - Business Wire
- 2 months ago - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - Business Wire
- 2 months ago - Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - Business Wire